05
Feb
2008
Genizon Biosciences, Inc.: Series D $31M
Posted in I - Series D, Q - 1Q08, R - INTERNATIONAL, X - Asthma, X - Biomarker, X - Crohn's, X - Schizophrenia
Genizon Biosciences (Canada) is a therapeutic target and biomarker development stage company focused on Crohn’s disease, psoriasis, asthma and schizophrenia has closed a $31M Series D. Participants include BTF B.V.
Fatal error: Call to undefined function php() in /home/onbiovcc/public_html/wp-content/themes/bx-blue-green/single.php on line 25